Lipid Effects of Peroxisome Proliferator-Activated Receptor-Δ Agonist GW501516 in Subjects With Low High-Density Lipoprotein Cholesterol
| Autor: | Nigel P. Jones, Eric Olson, Dennis L. Sprecher, Gregory L. Pearce |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Blood Glucose Male Apolipoprotein E medicine.medical_specialty Very low-density lipoprotein Time Factors Apolipoprotein B Cholesterol VLDL Peroxisome proliferator-activated receptor Blood lipids Fatty Acids Nonesterified GW501516 chemistry.chemical_compound Double-Blind Method Internal medicine medicine Humans Insulin Triglycerides Apolipoproteins B Dyslipidemias Hypolipidemic Agents Metabolic Syndrome chemistry.chemical_classification Analysis of Variance Chi-Square Distribution Apolipoprotein A-I biology Cholesterol Cholesterol HDL Cholesterol LDL Middle Aged medicine.disease PPAR gamma Thiazoles Treatment Outcome Endocrinology chemistry biology.protein Female lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine Biomarkers Lipoprotein |
| Zdroj: | Arteriosclerosis, Thrombosis, and Vascular Biology. 32:2289-2294 |
| ISSN: | 1524-4636 1079-5642 |
| Popis: | Objective— Peroxisome proliferator-activated receptor-δ–induced upregulation in skeletal muscle fatty acid oxidation would predict the modulation of lipid/lipoproteins. Methods and Results— GW501516 (2.5, 5.0, or 10.0 mg) or placebo was given for 12 weeks to patients (n=268) with high-density lipoprotein (HDL) cholesterol Conclusion— GW501516 produced significant changes in HDL cholesterol, LDL cholesterol, apoA1, and apoB. Fewer very LDL and larger LDL support a transition toward less atherogenic lipoprotein profiles. These data are consistent with peroxisome proliferator-activated receptor-δ being a potentially important target for providing cardiovascular protection in metabolic syndrome-like patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|